These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 28211251

  • 1. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
    Hu H, Luan L, Yang K, Li SC.
    Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
    [Abstract] [Full Text] [Related]

  • 2. Indirect costs assessment and intangible costs description of rheumatoid arthritis patients with biological therapy in Morocco: ECORAM Study.
    Zarrik H, Hassani AC, Rkain H, Allali F, Bahiri R, Ahid S.
    Int J Rheum Dis; 2024 Oct; 27(10):e15367. PubMed ID: 39373088
    [Abstract] [Full Text] [Related]

  • 3. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
    Hallert E, Husberg M, Kalkan A, Skogh T, Bernfort L.
    Scand J Rheumatol; 2014 Oct; 43(3):177-83. PubMed ID: 24354438
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study.
    Xu C, Wang X, Mu R, Yang L, Zhang Y, Han S, Li X, Wang Y, Wang G, Zhu P, Jin H, Sun L, Chen H, Cui L, Zhang Z, Li Z, Li J, Zhang F, Lin J, Liu X, Hu S, Yang X, Lai B, Li X, Wang X, Su Y, Li Z.
    Arthritis Care Res (Hoboken); 2014 Apr; 66(4):523-31. PubMed ID: 24023001
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
    Malhan S, Pay S, Ataman S, Dalkilic E, Dinc A, Erken E, Ertenli I, Ertugrul E, Gogus F, Hamuryudan V, Inanc M, Karaarslan Y, Karadag O, Karakoc Y, Keskin G, Kisacik B, Kiraz S, Oksel F, Oksuz E, Pirildar T, Sari I, Soy M, Senturk T, Taylan A.
    Clin Exp Rheumatol; 2012 Apr; 30(2):202-7. PubMed ID: 22546069
    [Abstract] [Full Text] [Related]

  • 9. Evolution of cost structures in rheumatoid arthritis over the past decade.
    Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, Bischoff S, Zink A, German Collaborative Arthritis Centres.
    Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
    [Abstract] [Full Text] [Related]

  • 10. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Balkan Tezer D, Hacibedel B, Akkoc N.
    Clin Exp Rheumatol; 2016 Apr; 34(6):1033-1037. PubMed ID: 27749224
    [Abstract] [Full Text] [Related]

  • 11. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M, Kavanaugh A.
    Clin Exp Rheumatol; 2012 Apr; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [Abstract] [Full Text] [Related]

  • 12. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.
    Pharmacoeconomics; 2005 Apr; 23(4):377-93. PubMed ID: 15853437
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P, Whiteford H, Vos T, Bertram M.
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [Abstract] [Full Text] [Related]

  • 15. Indirect costs of rheumatoid arthritis in Brazil.
    de Azevedo AB, Ferraz MB, Ciconelli RM.
    Value Health; 2008 Mar; 11(5):869-77. PubMed ID: 18489511
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
    Ma QS, Liang S, Xiao HW, Zhang SX, Zhuang GH, Zou YH, Tan HZ, Liu JC, Zhang YH, Xu AQ, Zhang L, Feng XX, Hu DS, Wang FZ, Cui FQ, Liang XF.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul 10; 38(7):868-876. PubMed ID: 28738457
    [Abstract] [Full Text] [Related]

  • 18. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
    Ruof J, Hülsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, Merkesdal S.
    Ann Rheum Dis; 2003 Jun 10; 62(6):544-9. PubMed ID: 12759292
    [Abstract] [Full Text] [Related]

  • 19. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
    Kvamme MK, Lie E, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2012 Sep 10; 51(9):1618-27. PubMed ID: 22539479
    [Abstract] [Full Text] [Related]

  • 20. The costs of rheumatoid arthritis.
    Allaire SH, Prashker MJ, Meenan RF.
    Pharmacoeconomics; 1994 Dec 10; 6(6):513-22. PubMed ID: 10155281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.